Clinical Applications and Validation of Probiotics: Exploring Therapeutic and Preventive Potential Across Diverse Medical Conditions

A special issue of Applied Microbiology (ISSN 2673-8007).

Deadline for manuscript submissions: closed (28 February 2025) | Viewed by 389

Special Issue Editor


E-Mail Website
Guest Editor
Department of Experimental Medicine, University of Salento, Lecce, Italy
Interests: microbiome; probiotics; preventive medicine; artificial intelligence in medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Probiotics have gained increasing attention for their role in and restoration of a healthy microbiota, which is crucial for overall health.

This joint Special Issue of Microorganisms and Applied Microbiology focuses on the use of probiotics in various clinical settings, with particular attention being paid to their role in the prevention and treatment of diverse diseases, including neuropsychiatric, autoimmune, metabolic, and gastrointestinal disorders.

The selection of probiotic strains is critical, as specific bacterial characteristics and properties must be tailored to address distinct clinical needs.

This Special Issue aims to showcase recent advances in the clinical validation of probiotic formulations and explore how novel probiotic blends can be integrated into therapeutic and preventive practices. By highlighting clinical studies and real-world applications, this issue seeks to provide valuable insights into the potential of probiotics as an adjunct or alternative approach in managing a wide array of medical conditions. 

You may choose our Joint Special Issue in Microorganisms.

Dr. Francesco Broccolo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Microbiology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • probiotics
  • microbiota
  • clinical validation
  • therapeutic applications
  • preventive therapy
  • novel probiotic blends
  • medical conditions
  • specific strains

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 3924 KiB  
Article
Transplantation of Fecal Flora from Patients with Atherosclerosis to Mice Can Increase Serum Low-Density Lipoprotein Cholesterol and Affect Intestinal Flora and Its Metabolites
by Liang Feng, Jianting Feng, Li He, Fu Chen, Xin Feng and Suwen Wang
Appl. Microbiol. 2025, 5(1), 29; https://doi.org/10.3390/applmicrobiol5010029 - 13 Mar 2025
Viewed by 96
Abstract
Atherosclerosis (AS) is emerging as a major global public health problem. Researchers are developing and implementing various anti-AS strategies. This study aimed to investigate gut microbiota and metabolite changes associated with elevated serum low-density lipoprotein cholesterol (LDL-c). Mice were divided into two equal [...] Read more.
Atherosclerosis (AS) is emerging as a major global public health problem. Researchers are developing and implementing various anti-AS strategies. This study aimed to investigate gut microbiota and metabolite changes associated with elevated serum low-density lipoprotein cholesterol (LDL-c). Mice were divided into two equal groups: Group C (mice with gut microbiota from healthy subjects) and Group B (mice with gut microbiota from AS). At the end of the 8-week study, blood samples were collected for blood lipid analysis; rectal feces were collected for microbial 16S rRNA sequencing analysis and metabolomics analysis. Our results showed that the B group significantly increased serum lipid levels of LDL-c. However, no statistically significant differences were observed in the richness and diversity of the gut microbiota, but we observed an increase in the ratio of Firmicutes to Bacteroidetes and an increase in the abundance of Parabacteroides Goldstein. In addition, untargeted metabolomic analysis of fecal samples revealed 128 metabolites that were differentially expressed between groups C and B. Notably, group B was found to have significantly increased levels of metabolites involved in lipid metabolism pathways, such as estrogen glucuronide, ginsenoside f1, Pe (16:1e/14,15-epete), and prostaglandin E1. Those data highlight the importance of understanding AS from the gut microbiota perspective and establish a foundation for future research on AS. Full article
Show Figures

Figure 1

Back to TopTop